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Normal constitutive and inducible CIITA activity is crit-Lineberger Comprehensive Cancer Center
ical for regulating proper expression of MHC class IIUniversity of North Carolina
molecules, whereas aberrant over- or underexpressionChapel Hill, North Carolina 27599–7295
of class II can result in autoimmune or immunodeficiency
diseases, respectively. Loss of CIITA activity leading to
the loss of class II expression has been implicated inSummary
one such immunodeficiency disease, known as bare
lymphocyte syndrome (BLS). While transcription factorsThe severe immunodeficiency type II bare lymphocyte
play a critical role in modulating temporal and tissue-syndrome (BLS) lacks class II MHC gene transcription.
specific gene expression in response to developmentalOne defect from a complementation group A type II
and physiological stimuli, significantly fewer inheritedBLS patient is a 24 aa deletion in the MHC class II
diseases have been characterized as being caused by
transactivator (CIITA). We show here that the molecu-
a defect in gene regulation as opposed to a defect in a
lar defect present in this protein is a failure of CIITA structural gene. The first such group of inherited dis-
to undergo nuclear translocation. This defect was eases identified as resulting from mutations in specific
mapped to a position-dependent, novel nuclear local- transcription factors was type II BLS (Hume et al., 1989;
ization sequence that cannot be functionally replaced Reith et al., 1995). In humans, the hallmark of this syn-
by a classical NLS. Fusion of this 5 aa motif to an drome is the loss of MHC class II expression and severe
unrelated protein leads to nuclear translocation. Fur- immunodeficiency. The clinical onset of BLS occurs in
thermore, this motif is not critical for transactivation the first year of life and is characterized by recurrent
function. This is a description of a genetic disease gastrointestinal, pulmonary, and respiratory infections
resulting from a novel defect in the subcellular local- (Arens et al., 1987). Lymphocytes are normal in number,
ization of a transcriptional coactivator. but they fail to activate and proliferate in response to
stimulation. BLS patients die in early childhood, usually
before the age of four.Introduction
Individuals afflicted with type II BLS can be divided
into one of at least four different complementationA critical step in initiating an immune response to foreign
groups coinciding with genetic mutations in proteinspathogens is the breakdown and presentation of pep-
that are important for the transcription of class II MHCtides derived from the invading species. These peptides
genes, notably RFX5, RFXAP, RFXANK, and CIITAare presented on the surface of B cells, dendritic cells
(Hauber et al., 1995; Peijnenburg et al., 1995; Douhanand macrophages in conjunction with molecules of
et al., 1996; Masternak et al., 1998; Yang et al., 1988).the class II major histocompatibility complex, thereby
Patients in complementation group A are defective forallowing recognition of the antigen by T cell receptors.
the CIITA coactivator. The CIITA gene was first clonedThis results in T cell activation and the stimulation of
by its ability to complement RJ2.2.5, a class II–negative
the immune response. MHC class II expression, consti-
cell line derived from Raji (Accolla, 1983; Steimle et al.,
tutive in B cells, is induced in a wide variety of cell types 1993). Several different CIITA defects have been identi-
by a number of cytokines and other agents (Kara and fied in complementation group A patients, including
Glimcher, 1991; Ting and Baldwin, 1993; Mach et al., nonsense and splicing defect point mutations (Bontron
1996). These agents stimulate the activity of the class et al., 1997). One specific CIITA gene defect that is found
II transactivator CIITA, the master regulator of MHC in cells from a group A BLS patient (BLS-2) lies outside
class II gene expression. CIITA activates the expression of all known functional domains defined for the protein.
of the class II gene products DR, DP, and DQ, as well It consists of a 72 bp deletion leading to an in-frame
as the invariant chain and DM genes. CIITA is not a deletion of a 24–amino acid (aa) exon (aa 940–963)
DNA-binding protein, but it does mediate class II gene (Steimle et al., 1993). The function of this apparently
transcription through the specific trimeric regulatory critical exon and the molecular effect of its deletion are
DNA sequences W/X/Y (Abdulkadir and Ono, 1995; completely unknown.
Chang and Flavell, 1995; Riley et al., 1995; Boss, 1997; In the current study, we undertook the identification
Westerheide et al., 1997). CIITA contains several func- of the specific role of the 24 aa exon deleted in the
tional domains typically associated with transcription complementation group A BLS-2 patient. The focus was
factors or coactivators, including an amino-terminal to determine how loss of this region of the protein leads
acidic domain, a proline-rich domain, and a serine/thre- to a defect in the ability of CIITA to activate the expres-
sion of MHC class II genes. The results show that thisonine-rich region. It also contains functionally important
domain functions as a novel nuclear localization se-
quence (NLS) critical for targeting the CIITA protein to† To whom correspondence should be addressed (e-mail: panyun@
the nucleus. The NLS in CIITA likely has unique proper-med.unc.edu).
ties because fusion of this immunodeficient form of‡ Present address: Howard Hughes Medical Institute, Yale University
School of Medicine, New Haven, Connecticut 06510. CIITA with a heterologous SV40 NLS fails to rescue
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BLS-2 cells was constructed (Figure 1A, CIITA-24aa).
As loss of this region results in the loss of CIITA activity
and MHC class II gene expression in the patient, we
initially determined whether this same mutation could
recapitulate the mutant CIITA inactivity in cell culture
lines. Wild-type CIITA or CIITA-24aa was transfected
into Cos-7 cells and examined for its ability to activate
a luciferase reporter gene under the control of the MHC
class II DR promoter. Whereas transfection of wild-type
CIITA strongly activated expression of the reporter gene,
CIITA-24aa failed to activate the same reporter (Figure
1B). This confirms the previous findings that the loss of
this 24 aa region in a BLS patient correlates with the
failure to express MHC class II genes (de Preval et al.,
1985; Lisowska-Grospierre et al., 1985; Steimle et al.,
1993). To better define the motif and to identify the
particular amino acids within the 24 aa exon that specifi-
cally caused the abrogation of CIITA activity, a series
of mutations or deletions of short amino acid segments
was constructed (Figure 1A). The actual mutated resi-
dues were selected because of their composition, which
may reflect possible functions. Two acidic residues were
mutated to alanine (CIITA mut.1), and a short stretch
of serine residues was also mutated to alanine (CIITA
mut.2). Neither mutation had any impact on the ability
of CIITA to stimulate expression from a class II promoter
(Figure 1B). In contrast, deletion of a stretch of five
predominantly basic amino acids (CIITA-5aa) was suffi-
cient to eliminate the transactivation potential of CIITA.
To rule out artifacts that may arise due to deletion muta-
genesis, the 5 aa region was also examined by site-
specific mutagenesis (CIITA mut.5aa). This CIITA mutant
was completely incapable of activating gene expression
from a class II MHC promoter. This minimal region con-Figure 1. Mutations in the BLS Region Disrupt the Transactivation
tained in aa 955–959 appears to be absolutely essentialAbility of CIITA
for the transactivation function of CIITA. Deletion of this(A) Schematic of the deletions or mutations of the CIITA 24 aa region
that is missing in BLS patients. Acidic, proline/serine/threonine-rich, region of CIITA in the BLS-2 patient accounts for the
and GTP-binding homologous domains of CIITA are indicated. failure of the CIITA protein to activate class II gene ex-
(B) Cos-7 cells were transfected with a luciferase reporter gene pression.
under the control of the HLA-DRA promoter (designated DR-luc)
and cotransfected with wild-type CIITA (lane 2) or the indicated
CIITA mutants (lanes 3–7). Twenty-four hours posttransfection, cells
Localization of the BLS Mutant CIITA Proteinwere harvested, extracts prepared and normalized to protein con-
by Immunofluorescencecentration, and luciferase activity of each extract determined. Acti-
vation of the DR-luc reporter by all constructs is set relative to 100% The 5 aa region identified as being critical for proper
activation by the wild-type CIITA (lane 2). Each category within the CIITA activity, RDLKK, bears some similarity to NLSs
experiment was performed in triplicate. Standard deviations are reported for other proteins (Jans and Hubner, 1996). In
shown. general, these motifs consist of a series of basic resi-
dues concentrated within a short 5–7 aa sequence. The
motif present in CIITA conforms to these specificationsproper CIITA localization and activity. This suggests that
this region may mediate interaction of CIITA with other by containing 3 basic residues, an arginine and two
lysines, although it is unusual in that the basic aminospecific proteins of the nuclear import pathway. This
paper reports a novel mutation in the NLS of a transcrip- acids are separated by an aspartic acid residue. If dele-
tion of the 24 aa exon in the BLS-derived CIITA resultstion factor leading to impaired function and resulting in
a human disease syndrome. in the loss of an NLS, then differences in cellular distribu-
tion should be detected between CIITA and its mutants.
To address this issue, full-length CIITA and the various
mutants were fused to an amino-terminal FLAG epitopeResults
and transfected into Cos-7 cells. Gene expression of
each of the constructs was under the control of an SV40Reproduction of Complementation Group A BLS
Mutant CIITA Activity in Cell Culture promoter. Anti-FLAG antibodies were used to determine
the subcellular distribution of the CIITA proteins (FigureTo examine the basis for the loss of CIITA activity in
cells from the BLS patient, a CIITA expression plasmid 2). Wild-type CIITA (Figure 2A) displayed a dual localiza-
tion pattern, with high levels of expression in the nucleusthat lacks the same 24 aa exon as that deleted in the
BLS Mutation in CIITA Affects Nuclear Translocation
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Figure 3. Subcellular Fractionation Demonstrates that Wild-Type
CIITA Exhibits Dual Subcellular Localization, while Mutation of the
BLS Domain Causes Retention of CIITA Predominantly in the Cyto-
plasm
Western blot analysis of nuclear and cytoplasmic fractions for the
presence of CIITA, GCN5, or TFIIB. Cos cells were cotransfected
with tagged CIITA and GCN5. Specific proteins were detected with
anti-FLAG (CIITA) or anti-Xpress (GCN5) antibodies. Endogenous
TFIIB staining demonstrates integrity of the nuclear extracts despite
the apparent absence of the CIITA mutant protein in these subfrac-
tions.
localization patterns similar to that seen for the wild-
type protein, consistent with the unmitigated ability of
these mutants to activate expression from class II MHC
promoters. In contrast, deletion of the 72 bp exon (CIITA-
24aa) resulted in a strictly cytoplasmic localization of
the CIITA protein. Site-specific mutation or deletion of
the 5 aa segment of CIITA also resulted in a complete
absence of the protein from the nucleus. Cytoplasmic
localization of the mutated CIITA molecules correlates
with the failure of these same mutants to activate gene
expression from the DR promoter.
Localization of CIITA Protein
by Subcellular Fractionation
To confirm the localization patterns of wild-type CIITA
and the BLS domain mutants, subcellular fractionation
experiments were performed. Cells transfected with
wild-type CIITA, CIITA-24aa, or CIITA-5aa were sepa-Figure 2. Mutation of the 5 aa Motif in the BLS Region of CIITA Is
Sufficient to Eliminate Nuclear Localization of the Protein rated into cytoplasmic and nuclear fractions and as-
FLAG-tagged wild-type CIITA (1.5 mg) (A) or the indicated CIITA sayed by Western blot analysis for the presence of the
mutants (B–F) were transfected into Cos-7 cells growing in 2-well CIITA protein (Figure 3). In accordance with the immuno-
chamber slides and assayed for subcellular localization. The cells fluorescence studies, wild-type CIITA was present in
were fixed at 24 hr posttransfection and stained with an anti-FLAG
both cytoplasmic and nuclear fractions, whereas mutantantibody/FITC-conjugated secondary antibody to assay for localiza-
CIITA lacking the 24 aa region was present almost en-tion of the CIITA proteins in transfected cells (A–F). Hoechst staining
tirely in the cytoplasmic fraction. Likewise, the CIITA-indicates the presence and location of nuclei in all cells (G–L). Repre-
sentative fields are shown. Wild-type CIITA (A) consistently shows 5aa protein was also strictly confined to the cytoplasm.
cytoplasmic and nuclear localization. Cytoplasmic localization of Integrity of the nuclear extracts was confirmed by West-
the BLS mutant forms of CIITA (B, E, and F) is shown by the failure ern blots using antibodies to the basal transcription fac-
of nuclei to stain with the FLAG-CIITA-specific antibody.
tor TFIIB, which is expected to be in the nuclear fraction
(Figure 3, lower panel).
In order to demonstrate the capacity of the Cos cellsas well as significant expression in the cytoplasm. To
determine whether the cytoplasmic expression of CIITA to support nuclear translocation of a transfected gene
product, cells were cotransfected with an expressionin these studies was simply the result of ongoing mRNA
and protein synthesis due to the constitutively active plasmid for GCN5, a histone acetyltransferase shown
to be active in the nuclear compartment (Brownell etSV40 promoter, cells were also incubated in the pres-
ence of actinomycin D to inhibit further transcription. al., 1996). Western blots detect GCN5 in the nuclear
fraction, showing that protein from a control plasmidThese cells still displayed dual nuclear and cytoplasmic
localization of CIITA (data not shown), suggesting a can be translocated to the nucleus. Cytoplasmic GCN5
may be either an inactive form or the result of increasedphysiological role for the protein in cytoplasm as well as
the nucleus. CIITA mut.1 and CIITA mut.2 both displayed expression in transfected cells. These data support the
Immunity
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Figure 5. BLS-Derived CIITA Mutants Retain Transactivation Ability
When Fused to GAL4
Cos cells were transfected with a Gal5-luciferase reporter plus GAL4
alone (lane 2), GAL4 fused to wild-type CIITA (lane 3), or GAL4 fused
to the indicated CIITA mutants (lanes 4–7). Luciferase activity was
assayed at 24 hr posttransfection and normalized to protein concen-
Figure 4. The CIITA 5 aa Motif Drives Nuclear Localization When tration of the extracts. Results are set relative to 100% activation
Fused to Green Fluorescent Protein of the Gal5-luc reporter by GAL4/CIITA (lane 2). Cos cells were
Cos-7 cells were transfected with green fluorescent protein alone transfected with the reporter plasmid alone as a negative control
([A] GFP), GFP fused to an SV40 NLS (B), GFP fused to one or four (lane 1).
copies of the CIITA 5 aa sequence proposed to function as a NLS
(C and D), or GFP fused to an unrelated basic sequence located
upstream of the BLS deletion site in CIITA (E). Fluorescence of
These experiments confirm that the 5 aa sequence ofthe fusion protein was observed at 24 hr posttransfection. 503
magnification. CIITA, RDLKK, is functioning as an NLS.
The 5 aa Motif Is Not Required for
Transactivation Functionhypothesis that a 5 aa motif is responsible for the nuclear
Mutation of the BLS domain results in the failure of CIITAlocalization of CIITA and suggest a molecular mecha-
to translocate to the nucleus. However, this mutationnism for the BLS phenotype resulting in the loss of CIITA
may also affect the ability of CIITA to transactivate targetactivity and MHC class II gene expression.
genes by altering or destroying an activation domain. To
distinguish between these two possibilities of a defect in
nuclear translocation versus transactivation, a series ofNuclear Translocation of a Heterologous Protein
Mediated by the 5 aa Motif fusion proteins was made between the yeast transcrip-
tion factor GAL4 and the CIITA mutants. The GAL4 pro-To determine if the 5 aa sequence of CIITA can function
independently as a nuclear localization signal, this se- tein used in these studies contained its own NLS and
DNA-binding domain but lacked the carboxy-terminalquence was fused to green fluorescent protein (GFP).
Expression of unmodified GFP transfected into Cos-7 activation domain. We assayed the ability of these fusion
proteins to activate luciferase gene expression from acells resulted in a diffuse fluorescent pattern present
throughout the cell (Figure 4A). Fusion of the NLS from promoter containing five GAL4 DNA-binding sites (Gal5-
Luc) (Figure 5). GAL4 alone is unable to activate reporterthe SV40 virus to GFP lead to a strong nuclear localiza-
tion (Figure 4B). Importantly, GFP fused to one (Figure gene expression, while GAL4 fused to full-length, wild-
type CIITA induced a 400-fold increase in expression.4C) or four copies (Figure 4D) of the 5 aa motif of CIITA
exhibited nuclear localization. This is a sequence-spe- Fusion of GAL4 to the BLS mutants lacking the 24 aa
or 5 aa motif, as well as CIITA mut.1, all resulted incific effect, as GFP fused to a sequence of basic amino
acids, RKKR, which is found N-terminal to the BLS re- similar degrees of activation. This data indicates that
mutations in the BLS region of CIITA do not impair thegion (CIITA aa 742–745) and fits the criterion of known
nuclear localization domains, displayed a diffuse fluo- ability of the protein to mediate activation of target
genes and that any activation domains within CIITA re-rescent pattern (Figure 4E). In addition, mutations of
this RKKR sequence did not affect CIITA transactivation main intact and functional. Therefore, the loss of the 24
aa exon in the group A BLS patient appears to affectability, indicating that this region is not functionally criti-
cal despite its homology to other NLS (data not shown). only the ability of CIITA to translocate to the nucleus
BLS Mutation in CIITA Affects Nuclear Translocation
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Figure 6. An SV40 NLS or 5 aa Motif Fused to the BLS-Mutated
CIITA Fails to Rescue Trascriptional Activation Ability
Cos cells were cotransfected with the DR-luc reporter and the indi-
cated CIITA constructs. For mutant constructs (lanes 4 and 6–11)
the SV40 NLS was fused to the amino terminus of CIITA-24aa [CIITA-
24aa (Nter NLS)] and CIITA-5aa [CIITA-5aa (Nter NLS)] or to the Figure 7. Subcellular Localization of Immunodeficient Forms of
CIITA Fused to a Heterologous NLScarboxyl terminus of CIITA-5aa [CIITA-5aa (Cter NLS)]. In another
set of constructs, the 5 aa motif was fused to the amino terminus Wild-type CIITA (A) or mutant CIITA fused to the SV40 NLS (B–D)
of CIITA-5aa [CIITA-5aa (Nter NLS)] or to the carboxyl terminus of or the 5 aa motif (E and F) in various locations were transfected into
CIITA-5aa [CIITA-5aa (Cter 5aa)], or the BLS deletion sequence was Cos-7 cells. Mutants are labeled as described in Figure 6. Twenty-
internally replaced with the SV40 NLS (CIITADNLS). Luciferase activ- four hours posttransfection, cells were fixed and incubated with
ity was assayed at 24 hr posttransfection and normalized to protein anti-FLAG antibody. FITC-conjugated secondary antibody was used
concentration of the extracts. Results are set relative to 100% acti- to visualize localization of the fusion proteins. Wild-type CIITA shows
vation of the DR-luc reporter by cotransfection with wild-type CIITA characteristic cytoplasmic and nuclear staining.
(lane 2). Presence of the SV40 NLS failed to rescue the activity of
the BLS-mutants. CIITA mutants that contained the 5 aa motif at
ectopic sites also failed to function.
these NLS- and 5aa-fused CIITA mutants were then as-
sayed for their ability to activate expression of a lucifer-
ase reporter gene under the control of the class II DR
without damaging the transactivation capacity of the promoter (Figure 6). If the NLS of CIITA and SV40 are
protein. interchangeable, then it would be expected that CIITA-
24aa (Nter NLS), CIITA-5aa (Nter NLS), CIITA-5aa (Cter
NLS), and CIITADNLS would function properly. Similarly,Inability of Heterologous NLSs to Rescue
the BLS-Derived Mutant CIITA Activity if the 5 aa motif acts in a position-independent manner,
then it would be expected that CIITA-5aa (Nter 5aa)and Localization
Given the hypothesis that the 5 aa motif present in the and CIITA-5aa (Cter 5aa) would also function properly.
However, none of these mutants exhibited any transacti-exon of CIITA deleted in the BLS patient is functioning
as an NLS, we wished to determine whether BLS-derived vation function. This demonstrates that the NLSs from
SV40 and CIITA defined by the BLS are not interchange-CIITA activity could be rescued by fusion to a conven-
tional NLS. The classical SV40 NLS was joined to the able and indicates that the 5aa motif functions in a posi-
tion-dependent manner.amino terminus of the CIITA mutants, CIITA-24aa [the
plasmid generated is denoted as CIITA-24aa (Nter NLS)] Immunofluorescent studies using these same mutants
were performed to assess the subcellular localizationand CIITA-5aa [CIITA-5aa (Nter NLS)], as well as to the
carboxyl terminus of the CIITA-5aa mutant [CIITA-5aa of CIITA variants fused to the SV40 NLS or 5 aa se-
quence. The various constructs were transfected into(Cter NLS)]. In addition, a mutant protein was con-
structed in which the SV40 NLS replaced the CIITA 5 Cos cells and localization of the fusion protein was
probed 24 hr later using an antibody to the FLAG epi-aa motif within the same location (CIITADNLS). We also
wished to assay whether the 5 aa motif could function tope. Expression of mutant forms of CIITA remained
restricted to the cytoplasm despite fusion of the SV40as an independent modular unit to rescue BLS-mutant
CIITA activity. Therefore, similar constructs were made NLS to the amino or carboxyl terminus (Figures 7B and
7C). Similarly, substitution of the CIITA 24 aa exon se-using the 5 aa motif and placing it at the amino or car-
boxyl terminus of CIITA-5aa [denoted CIITA-5aa (Nter quence with the SV40 NLS also failed to induce nuclear
translocation (Figure 7D). Addition of the 5 aa motif to5aa) and CIITA-5aa (Cter 5aa), respectively]. Each of
Immunity
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the ends of CIITA lacking the internal 5 aa sequence nuclear factors have been reported to contain this exact
motif, it shares similarity to the carboxy-terminal portionfailed to stimulate import of the mutant forms of CIITA
(Figures 7E and 7F). Localization of these mutants to of the bipartite NLSs present in the erb-A, thyroid b, and
estrogen steroid hormone receptors (Jans and Hubner,the cytoplasm correlates with the failure of the SV40
NLS and 5 aa to rescue the transactivation potential of 1996). Fusion of this domain to a green fluorescent pro-
tein is sufficient to cause GFP to accumulate in thethe BLS-mutant CIITA proteins. These data suggest that
while the 5 aa motif is functioning as an NLS in its native nucleus. Furthermore, mutation of this core domain
eliminates the ability of CIITA to enter the nucleus toposition and context, its activity is distinct from that of
the classical NLS. Therefore, the proper function of the transactivate gene expression from an MHC class II pro-
moter. The BLS-mutant CIITA protein itself remains con-BLS-mutant form of CIITA cannot be rescued through
fusion of the protein with a conventional NLS or the 5 formationally intact and fully functional in terms of its
ability to transactivate targets, as demonstrated by fu-aa motif in another context.
sion to a GAL4 factor. This suggests that the 5 aa motif
functions as a nuclear localization signal and that the
Discussion CIITA mutant form present in the BLS-2 patient lacks
the exon that contains this NLS. Loss of this NLS results
The hallmark of BLS is a failure to express MHC class in the failure of CIITA to translocate to the nucleus and
II antigens on the cell surface. Because of this failure, activate class II expression, causing the severe immuno-
cells are unable to present antigen peptides in conjunc- deficiency of BLS.
tion with the class II complex, resulting in the absence Conventional nuclear localization signals generally act
of CD41 T cell activation and initiation of an immune by mediating association of the NLS-containing protein
response to foreign pathogens. This disease was first with the karyopherin a/b1 heterodimer, resulting in
described nearly 20 years ago (Touraine and Betuel, docking to the nuclear pore complex and subsequent
1981), ultimately leading to the discovery of the gene translocation into the nucleus (Schlenstedt, 1996). To
responsible for one type of BLS (Steimle et al., 1993). date, two karyopherin a family member subtypes have
This gene, CIITA, is the master regulator of MHC class been described, karyopherin a and karyopherin a2 (Gor-
II expression. Deletion of a 72 bp exon of CIITA in a lich and Mattaj, 1996). The SV40 NLS is known to interact
complementation group A patient leads to its loss of with karyopherin a and a2 (Nadler et al., 1997). Complex
function, failure to activate the expression of class II formation with karyopherin b modifies or enhances the
genes, and the establishment of the severe immunodefi- ability of the karyopherin a family members to interact
ciency characteristic of BLS. However, the molecular with the NLS. However, fusion of the SV40 NLS to the
defect resulting from deletion of this region of CIITA has immunodeficient forms of CIITA failed to rescue normal
remained unclear. Therefore, this study undertook to localization and activity of the protein. The fact that the
examine specifically how loss of this region affects CIITA presence of an SV40 NLS is not sufficient to drive nuclear
activity, which should lead to a clearer understanding translocation of the BLS-derived mutant form of CIITA
of the origin and nature of BLS as well as helping to suggests that nuclear import of CIITA is not mediated
elucidate the mode of action of the CIITA protein and by the same karyopherin a/b family members responsive
potential control points in modulating its activity. to a classical NLS. The 5 aa NLS, deleted in the BLS
We demonstrate here that the region missing in CIITA form of CIITA, must be present to effect normal nuclear
from the BLS-2 patient is critical for the proper nuclear localization of the protein.
localization of the protein. The CIITA protein normally The question arises as to how the CIITA NLS specifi-
is present in both the cytoplasm and nucleus. Deletion cally mediates translocation to the nucleus. As the 5 aa
of the same 72 bps missing in the CIITA gene of the sequence alone can induce nuclear translocation when
BLS patient causes CIITA to be localized only in the fused to a heterologous protein, the most likely explana-
cytoplasm. It would be most desireable to demonstrate tion is that this motif is functioning as a recognition
localization patterns of endogenous CIITA protein. How- sequence for binding to other members of the karyo-
ever, due to extremely low levels of CIITA expression, pherin family distinct from those utilized by the classical
we were unable to reliably detect native CIITA under a NLS pathway, or it may mediate interaction with an as-
variety of conditions despite all attempts. Therefore, we yet-unidentified karyopherin family member. The evi-
made use of a cell culture system in which a transfected dence presented here indicates that the 5 aa motif of
CIITA gene is tagged with a FLAG epitope. Transfected CIITA is functioning as an NLS. When fused to GFP, one
CIITA has been used by our lab and others (Chang et copy of the 5 aa motif is sufficient to cause translocation
al., 1994; Zhou and Glimcher, 1995; Chin et al., 1997; of GFP. The role of this 5 aa motif in the CIITA protein is
Brown et al., 1998) to study CIITA activity and is pre- position dependent; while this motif can induce nuclear
sumed to function in a manner analogous to endoge- translocation when fused to the carboxyl terminus of a
nous CIITA. Characterization of the BLS-mutant form small protein such as GFP (approximately 27 kDa molec-
of CIITA by both immunofluorescence and subcellular ular weight), it is not capable of directing the import of
fractionation studies confirms its localization to be re- CIITA when fused to the amino or carboxyl terminus. The
stricted to the cytoplasm. Mutations within this region size, three-dimensional structure, and conformational
identify a critical core domain of 5 aa responsible for restraints of CIITA may restrict the 5 aa motif, suggesting
nuclear translocation of CIITA. The sequence of this that in order for the 5 aa motif to function properly as
core amino acid motif, RDLKK, contains a concentration an NLS for CIITA, it must be present in a specific context
and position within the protein. Alternatively, the CIITAof basic residues, indicative of an NLS. While no other
BLS Mutation in CIITA Affects Nuclear Translocation
169
5 aa motif may regulate complex formation with another complex, the involvement of this motif with nuclear im-
port and export will be of interest for future investiga-cytosolic protein containing its own NLS, allowing CIITA
tions.to cotranslocate into the nucleus at the same time. In
Several heritable diseases have been described re-either case, mutation or deletion of this region, as ob-
sulting from mutations in transcription factors. Muta-served in one form of BLS, prevents CIITA from properly
tions in Pit-1 lead to combined pituitary hormone defi-translocating into the nucleus and results in the cyto-
ciency (Pfaffle et al., 1992; Radovick et al., 1992);plasmic localization of the protein.
mutations in Brn-4 lead to X-linked hearing impairmentProteins that use the classical NLS-mediated import
(de Kok et al., 1995); mutations in RFXANK, RFX5, andpathway have interchangeable NLSs. However, not all
RFXAP lead to complementation groups B, C, and D ofnuclear localization signals are interchangeable, partic-
BLS, respectively (Durand et al., 1997; Masternak et al.,ularly among proteins that utilize different mechanisms
1998; Reith et al., 1988); mutations in CBFA-1 (Mundlosof nuclear import. Analogous to the mode of CIITA im-
et al., 1997) lead to cleidocranial dysplasia; and muta-port and its failure to be complemented by a SV40 NLS,
tions in the Pax family of transcription factors lead to acurrent evidence indicates that a variety of pathways
variety of congenital eye defects, including Waarden-regulate protein translocation across the nuclear pore
burg’s syndrome (Tassabehji et al., 1992). While p53complex. Recent studies have demonstrated that these
somatic mutations are recognized as the most frequentalternate pathways do not involve karyopherin a or b1
genetic abnormality in cancer, rare p53 germline muta-and are mediated by distinct NLSs. The hnRNP A1 pro-
tions have also been identified, leading to Li-Fraumenitein contains an “M9” NLS, which recognizes karyo-
hereditary cancer syndrome (Malkin et al., 1990). How-pherin b2 (Siomi and Dreyfuss, 1995). While karyopherin
ever, each of these transcription factor mutations affectb2 docks the NLS-containing protein to a similar set of
either the DNA-binding domain or the transactivationnuclear pore proteins (nucleoporins) as that utilized by
domain of the protein. In contrast, the mutation in CIITAkaryopherin b1, it recognizes an NLS distinct from the
that leads to one form of BLS in the complementationclassical NLS (Bonifaci et al., 1997), leading to the sug-
group A patient is the loss of a nuclear localization sig-gestion that each of the karyopherin b complexes recog-
nal. The molecular defect reported here is a descriptionnizes its own type of NLS. Karyopherin b2 also appears
of a novel mutation affecting the NLS of a transcriptionalto mediate the NLS-independent import of b-catenin
coactivator, which leads to a hereditary disease.(Fagotto et al., 1998). Like the karyopherin b family, dif-
ferent subtypes of karyopherin a exist and bind NLSs
with differing specificities and in a sequence-specific Experimental Procedures
manner. For example, the high-mobility group transcrip-
Cells and Plasmidstion factor lymphoid enhancer factor 1 (LEF-1) binds to
All mutants were constructed using the pcDNA3.FLAG.CIITA8 par-both karyopherin a and a2 through a classical NLS,
ent vector containing an 8 aa FLAG epitope upstream of the first
while a highly related transcription factor T cell factor 1 methionine of CIITA (Chin et al., 1997). CIITA-24aa was constructed
(TCF-1), which contains an NLS nearly identical to that by overlapping PCR using four primers: 1, (2071-GCCAAAGGCTTAG
TCCAACACC-2092); 2, (GCATCGATGATCCTCTGAGTCTGCACAAGof LEF-1, does not interact with either karyopherin a or
CTTTCC-2794); 3, 2(TCATCGATGCTCTGGGCCCTGTCTCAGGCCa2 (Prieve et al., 1998). An additional novel nuclear im-
CCAGG-2914); and 4, (3217-ACACCATGTCCGGAAGCACA-3198).port pathway has been demonstrated for the HIV TAT
Products from initial PCR reactions using primers 1/2 and 3/4 were
protein. Translocation of TAT is not competed by SV40 combined and reamplified with primers 1/4. The resulting product
NLS peptides and does not utilize the karyopherin a/b deleted bp 2818–2890 of CIITA. CIITA mut.1 and mut.2 were con-
structed by transformer site-directed mutagenesis (Clontech) ac-complex (Efthymiadis et al., 1998). These studies indi-
cording to the instructions of the manufacturer using mutageniccate that while the classical NLS pathway of nuclear
primers to alter 945-ED-946 to 945-AA-946 and 942-SSS-944 to 942-import is the most well characterized, other related but
AAA-944, respectively. CIITA mut.5aa, deleting bp 2863–2877, was
distinct intracellular pathways also serve to mediate nu- made using the QuikChange site-directed mutagenesis kit (Strata-
clear translocation. Specification of these alternate gene) and the primer 2847-CGAGCTCCCTGCTGTTTggggccccatc
pathways is likely determined by different types of NLSs. gataCTGGAGTTTGCGCTGG-2893, according to the instructions of
the manufacturer. CIITA-24aa (Nter NLS) and CIITA-5aa (Nter NLS)It is interesting to note that native CIITA has a dual
were made by initially inserting the SV40 NLS sequence (ATGCCGAAlocalization in the cytoplasm and nucleus, as shown by
GAAAAAGCGAAAGGTA) immediately downstream of the FLAGboth fractionation and immunofluorescence studies. It epitope in the pcDNA3.FLAG.CIITA8 parent vector by overlapping
is possible that this dual localization has functional PCR and reamplification. This NLS.CIITA vector was digested with
significance, as many transcription factors including AocI and BsrGI to remove a 2.5 kb fragment internal to the CIITA
gene and containing the BLS domain. AocI–BsrGI fragments (2.5STAT1, NF-AT, and NF-kB are controlled at the level of
kb) containing the mutated BLS region were isolated from CIITA-nuclear translocation (Liou and Baltimore, 1993; Rao et
24aa or CIITA-5aa and subcloned into the AocI–BsrGI-digestedal., 1997; Leonard and O’Shea, 1998). The ability of CIITA
NLS.CIITA vector to generate the NLS.CIITA variants. CIITA-5aa
to properly enter as well as exit the nucleus may be (Nter 5aa) was constructed by mutating the NLS of NLS.CIITA to
critical in regulating its capacity to transactivate target 5aa with QuikChange, using the primer CAAAGACGATGACGA
TAAAATGcgggacctaaagaaaaacgttCGTTGCCTGGCTCCACGCCCMHC class II genes. Therefore, restriction of CIITA to the
TGC, followed by subcloning in the AocI–BsrGI fragment from CIITA-nucleus may interfere with its transactivation potential. It
5aa. Carboxy-terminal NLS and 5 aa mutants were constructed byshould also be noted that CIITA is itself a GTP-binding
inserting a minipolylinker containing ClaI and BsiWI sites just prior
protein (J. Harton et al., unpublished data). Since GTP to the stop codon. Double-stranded oligos encoding the SV40 NLS
hydrolysis is a central event in the actual translocation (PKKKRKV) or the 5 aa motif (RDLKK) were ligated into ClaI/BsiWI-
digested parental vectors. CIITADNLS was prepared by mutatingthough the nuclear pore of the NLS-protein/importin
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aa 955–959 of pCDNA3.FLAG.CIITA8 parental vector to the SV40 by NIH grants RO1-AI29564–07 and AI41751 (J. T.) and by NIH-
NRSA grants CA-09156 (D. E. C.) and CA-73063 (D. J. T.). D. J. T.NLS by QuikChange, using the primer 2842-GCTGGGGAGCTCCCT
GCTGTTccgaagaaaaagagaaaggtcCTGGAGTTTGCGCTGGGCCC- is a Cancer Research Institute Fellow.
2897. GAL4/CIITA (pSGCIITA) was a generous gift from Jeremy Boss
(Riley et al., 1995). GAL4/CIITA mutant derivatives were prepared by
Received September 2, 1998; revised December 21, 1998.subcloning in the AocI–BsrGI fragment from the appropriate CIITA
mutant donor vectors. A 1.9 kb BamHI–EcoRI fragment containing
the hGCN5 cDNA from pRSET GCN5 was inserted into pCDNA3.1
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